Literature DB >> 16882327

Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.

Hideyuki Miyachi1, Ikuya Miki, Nobuo Aoyama, Daisuke Shirasaka, Yuko Matsumoto, Masanori Toyoda, Toshifumi Mitani, Yoshinori Morita, Takao Tamura, Shohiro Kinoshita, Yoshie Okano, Shunichi Kumagai, Masato Kasuga.   

Abstract

BACKGROUND: Recent years have witnessed a decrease in the rate of Helicobacter pylori eradication due to antimicrobial resistance, clarithromycin or metronidazole resistance in particular. As one of the alternatives to the standard regimens, levofloxacin-containing therapy has been considered a promising regimen. Nevertheless, there is a little information concerning the prevalence of levofloxacin resistance and this resistance mechanism.
MATERIALS AND METHODS: Levofloxacin susceptibility was examined using E-test in 507 H. pylori strains clinically isolated in Japan from 2001 to 2004. Mutation patterns in the quinolone resistance-determining regions of the gyrA and gyrB genes were evaluated, performing direct sequencing of 68 levofloxacin-resistant and 50 susceptible strains.
RESULTS: Primary levofloxacin resistance was found in 76 (15.0%) strains. Fifty-seven (83.8%) of 68 levofloxacin-resistant strains analyzed had point mutations in gyrA at Asn-87 or Asp-91, while seven (14.0%) of 50 susceptible strains had gyrA mutations. There was a significant difference in the occurrence of gyrA mutations between levofloxacin-resistant and -susceptible strains (p < .001). In levofloxacin-resistant strains, the occurrence of gyrA mutations at Asn-87 was most common regardless of minimal inhibitory concentration levels, and that of gyrA mutations at Asp-91 tended to be associated with low-level resistance. A double gyrA mutation at Asn-87 and Asp-91 might have an additional impact. As for gyrB, three (4.4%) of 68 levofloxacin-resistant strains with no susceptible strains had mutations.
CONCLUSIONS: Primary levofloxacin resistance was common in Japan and primarily related to gyrA mutations at Asn-87 and Asp-91.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882327     DOI: 10.1111/j.1523-5378.2006.00415.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  44 in total

1.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Authors:  Li-Hui Wang; Hong Cheng; Fu-Lian Hu; Jiang Li
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Molecular epidemiologic analysis and antimicrobial resistance of Helicobacter cinaedi isolated from seven hospitals in Japan.

Authors:  Emiko Rimbara; Shigetarou Mori; Mari Matsui; Satowa Suzuki; Jun-Ichi Wachino; Yoshiaki Kawamura; Zeli Shen; James G Fox; Keigo Shibayama
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

3.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

4.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

5.  Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population.

Authors:  Mariela López-Gasca; Jessy Peña; María-Alexandra García-Amado; Fabián Michelangeli; Monica Contreras
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

Review 6.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

7.  Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Toshihiro Nishizawa; Kenro Hirata; Hitoshi Tsugawa; Yoshimasa Saito; Sawako Okada; Seiichiro Fukuhara; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

8.  Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.

Authors:  Vincenzo De Francesco; Angelo Zullo; Cesare Hassan; Floriana Giorgio; Rosa Rosania; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2011-06-15

Review 9.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

Review 10.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.